If you have been reading about WADA Prohibited List and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Humans collect several species of Russula for food. There is a cultural divide toward interpretation of Russula edibility. In general, North American field guides tend to list mostly non-edible species and advise caution when consuming any member of the genus. In contrast, European field guides have a more favorable opinion and list more edible species. In the Pacific Northwest region of North America, only Russula brevipes parasitized with Hypomyces lactifluorum—known as lobster mushroom—is collected commercially. Several Russula species are sold in the markets of Izta-Popo Zoquiapan National Park (central Mexico): R. brevipes, R. cyanoxantha, R. mexicana and R. olivacea. In Tlaxcala, wild species sold in market include R. alutacea, R. cyanoxantha, R. delica, R. mariae, R. olivacea, R. romagnesia, and R. xerampelina. In Madagascar, species collected from introduced eucalypt forests include Russula madecassense, Russula prolifica, and several other species of minor importance, including some that have not yet been officially described. Russula is the most commonly consumed and economically important mushroom genus in Madagascar, particularly Russula prolifica and Russula edulis. This and other edible Russula are typically stripped of their cap cuticle before selling to make them more similar in appearance to the Agaricus bisporus. In Tanzania, Russula cellulata and Russula ciliata are sometimes used as food. Russula cyanoxantha is a popular edible throughout Asia, Europe, and the Pacific.
Human MHC class I and II are also called human leukocyte antigen (HLA). To clarify the usage, some of the biomedical literature uses HLA to refer specifically to the HLA protein molecules and reserves MHC for the region of the genome that encodes for this molecule, but this is not a consistent convention. The most studied HLA genes are the nine classical MHC genes: HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, and HLA-DRB1. In humans, the MHC gene cluster is divided into three regions: classes I, II, and III. The A, B and C genes belong to MHC class I, whereas the six D genes belong to class II. MHC alleles are expressed in codominant fashion. This means the alleles (variants) inherited from both parents are expressed equally:
Hormone replacement therapy, including gender-affirming hormone therapy, stimulates the growth of glandular and adipose tissue through estrogen supplementation. In menopausal women, HRT helps restore breast volume and skin elasticity diminished by declining estrogen levels, typically using oral or transdermal estradiol. In gender-affirming hormone therapy, breast development is induced through feminizing HRT, often combining estrogen with anti-androgens to suppress testosterone. Maximum growth is usually achieved after 2–3 years. Factors such as age, genetics, and hormone dosage influence outcomes.
American chemist and psychopharmacologist Alexander Shulgin reported he synthesized MDMA in 1965 while researching methylenedioxy compounds at Dow Chemical Company, but did not test the psychoactivity of the compound at this time. Around 1970, Shulgin sent instructions for N-methylated MDA (MDMA) synthesis to the founder of a Los Angeles chemical company who had requested them. This individual later provided these instructions to a client in the Midwest. Shulgin may have suspected he played a role in the emergence of MDMA in Chicago. Shulgin first heard of the psychoactive effects of N-methylated MDA around 1975 from a young student who reported "amphetamine-like content". Around 30 May 1976, Shulgin again heard about the effects of N-methylated MDA, this time from a graduate student in a medicinal chemistry group he advised at San Francisco State University who directed him to the University of Michigan study. She and two close friends had consumed 100 mg of MDMA and reported positive emotional experiences. Following the self-trials of a colleague at the University of San Francisco, Shulgin synthesized MDMA and tried it himself in September and October 1976. Shulgin and David E. Nichols first reported on MDMA and its psychoactive effects in humans in a presentation at a conference in Bethesda, Maryland in December 1976. This conference paper was subsequently formally published in 1978.
Sources: en.wikipedia.org
== Books == Kenneth Clarke, Kind of Blue, Macmillan, 2016, ISBN 1-509-83719-1 Michael Heseltine, Raising The Sights – A Tory Perspective, in the Primrose League Gazette, vol.91, no.2, Aug/Sept 1987 edition, London. Julian Critchley, Heseltine – The Unauthorised Biography, André Deutsch, London, September 1987, ISBN 0-233-98001-6. Michael Crick, Michael Heseltine: A Biography, Hamish Hamilton, 1997, ISBN 0-241-13691-1. Heseltine 2000, Heseltine's autobiography, written with the acknowledged assistance of his lifelong friend Anthony Howard. Edward Pearce, The Golden Talking-Shop, Oxford University Press, 2016, ISBN 0-198-71723-7, a history of the Oxford Union Society during the first half of the twentieth century, based on official minutes. Alexander Stevenson, The Public Sector: Managing the Unmanageable, 2013 (Contributor) Anne Heseltine, Michael Heseltine, Thenford: The Creation of an English Garden, Head of Zeus, 2016, ISBN 978-1784979737 Michael Heseltine, From Acorns to Oaks: An Urgent Agenda to Rebuild Britain, Biteback Publishing, 2025, ISBN 9781785909801
Dephosphorylation is commonly done using calf-intestinal alkaline phosphatase (CIAP) which removes the phosphate group from the 5′ end of digested DNA, but note that CIAP is not easy to inactivate and can interfere with ligation without an additional step to remove the CIAP, thereby resulting in failure of ligation. CIAP should not be used in excessive amount and should only be used when necessary. Shrimp alkaline phosphatase (SAP) or Antarctic phosphatase (AP) are suitable alternative as they can be easily inactivated.
Not all cnidarians reproduce sexually, but many species have complex life cycles of asexual polyp stages and sexual medusae stages. Some, however, omit either the polyp or the medusa stage, and the parasitic classes evolved to have neither form. Cnidarians were formerly grouped with ctenophores, also known as comb jellies, in the phylum Coelenterata, but increasing awareness of their differences caused them to be placed in separate phyla. Most cnidarians are classified into four main groups: the almost wholly sessile Anthozoa (sea anemones, corals, sea pens); swimming Scyphozoa (jellyfish); Cubozoa (box jellies); and Hydrozoa (a diverse group that includes all the freshwater cnidarians as well as many marine forms, and which has both sessile members, such as Hydra, and colonial swimmers (such as the Portuguese man o' war). Staurozoa have recently been recognised as a class in their own right rather than a sub-group of Scyphozoa, and the highly derived parasitic Myxozoa and Polypodiozoa were firmly recognized as cnidarians only in 2007. Most cnidarians prey on organisms ranging in size from plankton to animals several times larger than themselves, but many obtain much of their nutrition from symbiotic dinoflagellates, and a few are parasites. Many are preyed on by other animals including starfish, sea slugs, fish, turtles, and even other cnidarians. Many scleractinian corals—which form the structural foundation for coral reefs—possess polyps that are filled with symbiotic photo-synthetic zooxanthellae.
Sources: en.wikipedia.org
== Inventions == In 2023, she and an investigative team created a "Floor and small surface cleaner formula without water in its formulation presented in fast dissolving crystals with antibacterial effect" as well as "Compact powder Compact powder soap that dissolves quickly in the time necessary to ensure hand cleaning with moisturizing effect" those inventions were recognized by International Invention and Innovation Competition in Canada (iCAN). Her most awarded invention is the "Emulsion type cosmetic cream for face and body with moisturizing effect formulated with sinami (Oenocorpus mapora H. Karst)". This patent was created in collaboration with Dr. Luciana de la Fuente Carmelino and Mg. Juana Patricia Lozada Huancachoque, and it received the golden medals at the KIWIE Awards in 2024. Their others two inventions, that received this award, were "Formula and application method for the cleaning of cloudiness generated by weathering in glass containers" and "Toothpaste in tablet form free of water in its formulation with essential oils as antimicrobial active ingredients".
In 2024, the Council of Europe adopted the Framework Convention on Artificial Intelligence and Human Rights, Democracy and the Rule of Law, the first legally binding international treaty governing artificial intelligence.
==== New Zealand ==== Taco Bell officially opened its first New Zealand location on November 12, 2019, in the suburb of New Lynn, Auckland. As of January 2023, there are 14 Taco Bell restaurants across New Zealand; 10 on the North Island and four on the South Island. By city, there are seven in Auckland, three in Christchurch and one each in Dunedin, Rotorua, Taupiri and Wellington. There are two outlets at airports in New Zealand, one at Auckland Airport and the other at Christchurch Airport.
Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an enzyme that in humans is encoded by the ERAP1 gene. This M1 zinc aminopeptidase is involved in the antigen processing and presentation pathway. ERAP1 is mainly located in the endoplasmic reticulum (ER), where it trims peptides at their N-terminus, adapting them for presentation by MHC class I molecules (MHC-I).
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.